<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01777802</url>
  </required_header>
  <id_info>
    <org_study_id>12-008383</org_study_id>
    <nct_id>NCT01777802</nct_id>
  </id_info>
  <brief_title>Monitoring Anti-Prostate Cancer Immunity Following Stereotactic Body Radiotherapy (SBRT)</brief_title>
  <acronym>SBRT</acronym>
  <official_title>Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and
      systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been
      identified, including low intratumor expression of antigens and elevated expression of
      inhibitory co-regulatory molecules. An effective immunotherapy is one which would induce
      necrotic cell death and  proinflammatory cytokine production. Stereotactic Body Radiotherapy
      (SBRT) which delivers conformal, tumor-ablating radiation dose may be an effective means of
      conditioning solid tumors favorable to the initiation of robust antitumoral immune
      responses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Induction of anti-prostate cancer immunity</measure>
    <time_frame>Before, during and after Stereotactic Body Radiotherapy (SBRT)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Oligometastatic Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Oligometastatic Prostate Cancer</arm_group_label>
    <description>Prostate cancer patients with &lt;4 metastatic lesions are eligible to enroll in this observational study.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Oligometastatic prostate cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Oligometastatic prostate cancer patients with &lt; 4 metastatic lesions that are
             amenable to Stereotactic Body Radiotherapy (SBRT)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean S Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Krco, Ph.D.</last_name>
      <phone>507-774-5667</phone>
    </contact>
    <contact_backup>
      <last_name>Mary Ann Billeter</last_name>
      <phone>(507) 284-4561</phone>
      <email>billeter.maryann@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sean S Park, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>January 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sean S. Park</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
